Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Armata Pharmaceuticals, Inc.

Market Cap 260M 227M 210M 197M 368M 24.5B 371M 2.49B 963M 12.06B 975M 954M 41.94B P/E 2026 *
-1.86x
P/E 2027 * -5.28x
Enterprise Value 260M 227M 210M 197M 368M 24.5B 371M 2.49B 963M 12.06B 975M 954M 41.94B EV / Sales 2026 *
118x
EV / Sales 2027 * 94.5x
Free-Float
31.47%
Yield 2026 *
-
Yield 2027 * -
05-13 Armata pharmaceuticals announces first quarter 2026 results and provides corporate update RE
05-13 Armata Pharmaceuticals, Inc. Enters into A Secured Credit Agreement with Innoviva Strategic Opportunities LLC CI
05-13 Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Armata Pharmaceuticals Inc Secures FDA Fast Track Designation For AP-SA02 CI
04-27 Armata Pharmaceuticals, Inc. Appoints Daniel B. Gilmer, Ph.D. to Its Board of Directors, Effective April 24, 2026 CI
04-26 Zambon Spa, Insmed Incorporated, Novabiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, Csl Behring, and Others Announces Brensocatib Clinical Progress and Approvals for Non-Cystic Fibrosis Bronchiectasis CI
03-25 Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-24 Armata Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
03-19 Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update RE
02-23 Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment MT
02-23 Armata Pharmaceuticals receives FDA qualified infectious disease product designation RE
02-23 Armata Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product Designation for AP-SA02 CI
01-26 Armata Pharmaceuticals, Inc. Enters into Amendments to Four Existing Credit Agreements CI
1 day+0.28%
1 week-6.60%
Current month-13.34%
1 month-12.81%
3 months-15.61%
6 months+14.94%
Current year+12.74%
1 week 6.37
Extreme 6.3701
7.64
1 month 6.37
Extreme 6.3701
8.92
Current year 5.66
Extreme 5.66
14.98
1 year 1.81
Extreme 1.81
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 2023-07-10
Director of Finance/CFO 42 2024-08-15
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 2019-05-08
Director/Board Member 68 2019-10-09
Director/Board Member 66 2020-02-11
Date Insider Type Main position Quantity % Market Cap.
04-23Free

Director

51,280 0.1400%
03-13Tax

Public Communications Manager

1,030 0.0028%
03-13Tax

Chief Executive Officer

4,919 0.0135%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-6.60%+266.84%+365.79% 260M
+1.44%-1.25%+64.25%+114.23% 55.19B
+4.60%+3.02%+57.38%+48.98% 45.75B
-1.44%+0.39%-14.68%-17.33% 22.98B
-2.69%-2.10%-6.70%+374.02% 20.76B
+3.22%-0.84%+27.88%-20.46% 16.26B
+0.58%+1.08%+18.85%-37.32% 15.42B
-1.01%-2.30%+28.59%+174.08% 13.05B
+4.95%+11.70%+125.78%+252.19% 12.45B
+3.07%+0.14%+29.05% - 12.37B
Average +1.30%+1.49%+59.72%+139.35% 21.45B
Weighted average by Cap. +1.63%+1.47%+41.05%+101.48%

Financials

2026 *2027 *
Net sales 2.2M 1.92M 1.78M 1.67M 3.12M 207M 3.14M 21.06M 8.16M 102M 8.26M 8.08M 355M 2.75M 2.4M 2.22M 2.08M 3.9M 259M 3.93M 26.33M 10.19M 128M 10.32M 10.1M 444M
Net income -172M -150M -139M -130M -244M -16.21B -245M -1.65B -637M -7.98B -645M -631M -27.75B -66.35M -57.89M -53.59M -50.24M -94.06M -6.26B -94.72M -635M -246M -3.08B -249M -244M -10.71B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
26-06-18 7.080 $ +0.28% 21,260
26-06-17 7.060 $ +3.98% 33,694
26-06-16 6.790 $ -1.74% 152,439
26-06-15 6.910 $ -8.84% 41,675
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.080USD
Average target price
17.50USD
Spread / Average Target
+147.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!